Aktis Oncology, Inc.
(NASDAQ: AKTS)
Balfour Capital Group has issued a buy recommendation
for Aktis Oncology, Inc. (NASDAQ: AKTS) on March 3rd, 2026.
Aktis Oncology Inc. (“Aktis Oncology”) is a clinical-stage biotechnology company developing targeted radiopharmaceutical therapies for the treatment of solid tumors. The company utilizes a proprietary miniprotein radioconjugate platform designed to deliver radioactive isotopes directly to cancer cells, enabling highly targeted tumor destruction while minimizing exposure to surrounding healthy tissue. Operating segments consist primarily of research and development activities focused on the discovery and clinical advancement of radiopharmaceutical oncology candidates. The company’s lead program targets Nectin-4 expressing tumors, including locally advanced or metastatic urothelial cancer, through the development of radioconjugate therapies designed for precision delivery of radioisotopes.
Post Recommendation Price Trend Chart
The chart’s commencement marks the instance of our stock recommendation.
- We have established a Buy recommendation at $20.22 on March 3rd, 2026.
- Our designated price target stands at $35.00
Analysts Research
With steadfast dedication to thorough research, Balfour Capital Group engages with esteemed analysts and companies, evident below, to amplify and elevate our proficiency. This collaborative approach enriches our findings, granting readers and researchers a profound comprehension of the rationale behind our recommendations and research objectives.
View More
2025 Q4 EARNINGS REPORT
A Q4 report evaluates company financials for investors.
View More
THOMSON REUTERS
Thomson Reuters delivers global financial, legal, and business information to professionals.
View More
ARGUS QUANTITATIVE
Argus Quantitative analyzes energy, commodities, and finance with data analytics.
View More
ARGUS ANALYST
Argus Analyst Notes offers timely investment recommendations, insights.
Balfour Capital Group wants to clarify that our recommendation to Buy Aktis Oncology, Inc. (NASDAQ: AKTS) is based on thorough research conducted by our dedicated teams.
We invest significant time and resources in analyzing market trends, financial data, and industry insights to provide well-informed guidance.
However, it is important to note that our recommendation does not guarantee any specific financial outcomes. The decision to act on our recommendation should be made at your discretion. Please be aware that investments carry inherent risks, and the value of investments can fluctuate, potentially resulting in financial loss.
